CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for United Therapeutics Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

United Therapeutics Corporation
1000 SPRING ST
Phone: (301) 608-9292p:301 608-9292 SILVER SPRING, MD  20910  United States Ticker: UTHRUTHR
Business Summary
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Martine A.Rothblatt 68 6/26/2016 1/1/1996
President, Chief Operating Officer MichaelBenkowitz 51 6/26/2016 6/26/2016
Lead Independent Vice Chairman of the Board ChristopherPatusky 59 8/1/2007 10/24/2002
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Steadymed Ltd 5 Oppenheimer Street REHOVOT Israel
SteadyMed Therapeutics, Inc. 22a Raul Wallenberg St. Tel-Aviv Israel
LUNG BIOENGINEERING INC 1040 SPRING ST SILVER SPRING MARYLAND US
Miromatrix Medical Inc 6455 Flying Cloud Drive, Suite 107 EDEN PRAIRIE MN United States

Business Names
Business Name
1109 Spring Managing Holdings, LLC
1109 Spring Managing Member, LLC
1111 Spring Holdings, LLC
20 additional Business Names available in full report.

General Information
Number of Employees: 1,168 (As of 12/31/2023)
Outstanding Shares: 47,058,545 (As of 2/14/2024)
Shareholders: 31
Stock Exchange: NASD
Federal Tax Id: 521984749
Fax Number: (301) 608-9291


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024